The F1174L mutation bears strong oncogenic capacity and correlates with MYCN amplification, potentiating the oncogenic activity of MYCN in neuroblastoma, and is linked to acquired resistance to crizotinib [30, 49]. Here, MYCN is linked to neuroblastoma.